UNSPSC 51284403: Ceftobiprole medocaril

This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N99027V28J. European Medicines Agency schedules Ceftobiprole medocaril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25721. Ceftobiprole medocaril generally arises in the molecular formula C26H25N8O11S2.NA.

UNSPSC 51284403 Ceftobiprole medocaril is a Commodity code that in recent state and local procurement shows little activity aligned with its nominal pharmaceutical specification. The code is designed to classify a specific antibiotic active ingredient, yet the recent opportunities tagged under it diverge substantially: the Illinois Department of Public Health's piggyback pharmaceutical warehouse order under MMCAP Infuse procured Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets rather than ceftobiprole; Seminole County, Florida's IFB solicited Naloxone and Safe Drug Deactivation Systems, an opioid antagonist and harm-reduction equipment unrelated to the code's scope. When a Commodity code shows mismatched tagging, the actual procurement intent differs from the code name, and vendors pursuing this code should verify the issuing body's specific product or active-ingredient requirements rather than rely on the code alone. State and local health departments and counties are the primary issuing bodies using this code tier, though the recent sample suggests their tagging practices may not align tightly with UNSPSC taxonomy at the Commodity level.

The geographic spread of recent activity spans Illinois and Florida, with health department and county community health programs as the primary buyers. The Illinois contract, awarded on an IFB basis to Chartwell Rx LLC for $2,999,999.11 over three years (12 months initial term plus two renewal options), reflects typical state pharmaceutical cooperative-purchasing arrangements through consortia such as MMCAP. Seminole County's solicitation, issued June 30, 2026 with response due July 26, 2023 (a date error in the source), required quarterly deliveries and included FEMA funding contingencies and E-Verify compliance. Neither opportunity specified enterprise set-asides or local-vendor preferences. Given the mismatch between code scope and actual solicitations, this code warrants close review of individual RFQs and IFBs rather than assumption of ceftobiprole demand.